Contact: Ralph Barry, Chief Business Officer, Aegis Therapeutics LLC
1-858-618-1400 Ext. 102, Email: rbarry@aegisthera.com

Aegis Therapeutics Announces Use of Intravail® in a Positive Phase 2 Study of DFN-02 for Acute Migraine

San Diego, CA, June 28, 2017 – Aegis Therapeutics announces positive Phase 2 results of DFN-02 using Intravail® technology. Dr. Reddy’s Laboratories in collaboration with Promius Pharma, LLC (a wholly owned subsidiary of DRL) is developing DFN-02, a novel intranasal migraine treatment using Intravail for the acute treatment of adults with migraine with or without […]

Aegis Awarded 10th Patent for Fast Acting Migraine Nasal Spray Treatment

SAN DIEGO, CA June 22, 2017/ NASDAQ — Aegis Therapeutics LLC announced today that it has been awarded Korean Patent No. 1719008, providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan. Human clinical trials have shown that […]

Dauntless Pharmaceuticals Announces Positive Data from Phase 1 Study Investigating Octreotide Formulation for Intranasal Delivery

SAN DIEGO, May 4, 2017 /PRNewswire/ — Dauntless Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development of specialty therapeutics, today announced positive results from its two-part, Phase 1 pharmacokinetic/pharmacodynamic study evaluating DP1038, a novel formulation of octreotide acetate for intranasal administration. “This trial achieved all its endpoints confirming that therapeutic doses of […]

Aegis’ Protek® Excipients Provide A Superior Alternative To Polysorbates In Preventing Protein Aggregation And Unwanted Oxidative Damage And Immunogenicity

SAN DIEGO, CA March 23, 2016 — Biotherapeutics incorporating alkylglucosides rather than polysorbates are likely to achieve substantial commercial benefits and a strong and differentiable market franchise for innovator biotherapeutics and biosimilars. Aggregation-induced neutralizing antibodies and anaphylactic reactions sometimes associated with polysorbates are serious and growing concerns of both the FDA and the European Medicines […]

Aegis Awarded 8th Patent for Fast Acting Migraine Nasal Spray Treatment

SAN DIEGO, CA March 17, 2016/Marketwire — Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 9,283,280, its eighth patent, third in the US, providing fast acting formulations for triptans, a class of drugs that are effective in treating migraine headaches which include sumatriptan, zolmitriptan, naratriptan, rizatriptan, eletriptan, almotriptan and frovatriptan.  […]

Aegis Awarded Russian Patent for Non-Invasive Delivery of Triptan Anti-Migraine Drugs

SAN DIEGO, CA  Sept. 1, 2015/MarketWire — Aegis Therapeutics LLC announced today that it has been awarded its first Russian patent providing expanded coverage for non-invasive delivery of triptan anti-migraine drugs via a simple metered nasal spray. Newly issued Russian Patent No. 2554814, titled: “Compositions for drug administration”, covers fast acting drug formulations utilizing Aegis’ […]

Aegis Therapeutics Awarded Third Patent for Metered Nasal Spray Parathyroid Hormone (PTH) Peptide Drug Formulations

SAN DIEGO, CA  Aug 27, 2015/MarketWire — Aegis Therapeutics LLC announced today that it has been awarded US Patent No. 9,114,069 titled “Antibacterial Compositions for Drug Administration” providing non-toxic formulations of parathyroid hormone and related analogs, including teriparatide (PTH 1-34), suitable for injectable or metered nasal spray administration having intrinsic antimicrobial activity.  The patent formulations […]

Aegis Awarded Chinese and Japanese Patents for Non- Invasive Delivery of Triptan Anti-Migraine Drugs

SAN DIEGO, CA  Aug 11, 2015/MarketWire — Aegis Therapeutics LLC announced today that it has been awarded foreign patents providing expanded coverage for non-invasive delivery of triptan anti-migraine drugs via a simple metered nasal spray. Newly issued Chinese Patent No. ZL200980157305.0 and Japanese Patent No. 5752048, both titled: “Compositions for drug administration”, cover fast acting […]

Dauntless Pharmaceuticals and Aegis Therapeutics Announce Licensing Agreement

SAN DIEGO, July 21, 2015 /PRNewswire/ — Dauntless Pharmaceuticals, Inc. (Dauntless), a biopharmaceutical company focused on the development of specialty drugs and Aegis Therapeutics, LLC (Aegis) today announced a licensing agreement providing Dauntless’ access to Aegis’ Intravail® drug delivery technology for an undisclosed oncology application and an option for three additional drugs. Financial terms were not disclosed. […]

Aegis Awarded U.S. Patent No. 8,927,497 for Non- Invasive Delivery of Anti-Seizure Drugs

SAN DIEGO, CA Feb 18, 2015/MarketWire — Aegis Therapeutics LLC announced today that it has been awarded U.S. Patent No. 8,927,497 providing broad coverage for non-invasive delivery of anti-seizure drugs via a simple metered nasal spray. The rapidly acting formulations utilize Aegis’ patented Intravail® transmucosal absorption enhancer technology. Aegis now has twenty-one issued patents related […]